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Undergoing anabolic phosphorylation by intracellular kinases to form 
nucleoside triphosphates, nucleoside reverse transcriptase inhibitors (NRTIs), are 
the leading antiretroviral agents for the treatment of human immunodeficiency 
virus. Phosphorylation rates of the endogenous nucleosides and their corresponding 
analogs are governed by intracellular and extracellular factors. A total synthesis 
and molecular dynamic study of didanosine is presented to gain insight into the 
differences in phosphorylation between endogenous nucleosides and their analogs. 
2 
Introduction 
Hunlan immunodeficiency virus (HIV) is a retrovirus and the formative cause of acquired 
immunodeficiency syndrome (AIDS). Reverse transcriptase is an RNA-dependent DNA 
polymerase that converts viral RNA (+) to a fonn, DNA, which can be incorporated into 
the host's genome. The two leading therapeutic families of inhibitors of reverse 
transciptase are the non-nucleoside inhibitors (NNRTIs) and the nucleoside inhibitors 
(NRTIs). NNRTIs work by binding to RT and bring about a change in the binding 
pocket. They are targeted at allosteric sites of reverse transcriptase, i.e, at nonsubstrate 
binding sites. NRTls, as the name indicates, are biochemical variations of the "normal" 
or endogenous nucleosides produced inside the cell. They must be phosphorylated by a 
combination of intracellular enzymes to their active triphosphate (TP) forms in order to 
be used as a substrate in DNA synthesis. Once they are converted to their active TP 
form, they compete with the proviral DNA substrates for binding sites on reverse 
transcriptase and act as chain terminators if incorporated into nascent viral DNA. 1 The 
nucleoside analogs are specific to reverse transcriptase inhibiton and have mininlum 
inhibitory effects on other DNA polymerases. There are some toxic effects that may 
arise due to inhibition ofy-DNA polymerase in mitochondria. Approved NRTIs are 
orally bioavailable and have a short serum half-life, yet their intracellular half-life is 
relatively longer. 1 FDA-approved compounds that resemble both endogenous purine and 
pyrimidine nucleosides include abacavir (ABC), tenofovir disoproxil (PMP A), 
zidovudine (ZDV), stavudine (d4T), lamivudine (3TC), salcitabine (ddC), and didanosine 
(ddI).2 All of these compounds act as chain tenninators due to the lack ofa 3'·hydroxyl 
t 
group on the ribose ring. 
3 
Nucleoside Analogs are Prodrugs 
Kinases are enzymes that facilitate in the transfer of a phosphoryl group from adenosine 
triphosphate (ATP) to an acceptor. There are numerous types of acceptors because 
phosphorylation is used by many biological processes. Nucleoside diphosphate kinase 
(NDPK) is a very important enzyme to take into consideration when dealing with the 
development of alltiretroviral treatments (NRTls) due to their lack of 3' ... OH groups on 
the ribose rings of nucleoside analogs.3 Antiviral analogs are generally considered to be 
phosphorylated by the same series of cellular kinases as those that act on the natural 
nucleotides. Activation of analogs into the mono- and diphosphate forms is orchestrated 
by nucleoside kinases and nucleoside monophosphate kinases. This is accompolished 
with various degrees of specificity, i.e, purine analogs are phosphorylated under a 
different set of enzymes and conditions than pyrimidines.4 In contrast though, activation 
to the triphosphate form is achieved by NDP kinase, which is nonspecific for the 
nucleobase moiety of the donor and acceptor nucleotide. It has previously been 
mentioned that the 3' -OH on the ribose ring plays an important role in the 
phosphorylation mechanism ofNDP kinase. Reasons for this could be due to hydrogen-
bond formation between the gamma phosphate and the 3' ~OH or donation of a proton to 
the phosphate group.s If considered a vital role in the mechanism, it could account for 
the reason why dideoxy nucleotide analogs like ddI-DP are phosphorylated at such a low 
rate. The phosphorylation mechanism for purine analogs and the associated enzytnes 
necessary for purine nletabolism are discussed in this paper. 
4 
Steps for Phosphorylation 
Just like endogenous nucleosides, NRTls make use of the nucleotide synthesis 
and phosphorylation pathways in the host cell. The route to the diphosphate fonn varies 
between the two different groups ofnucleosides, purine and pyrimidine, yet the last step 
in the pathway, shared by most endogenous nucleosides and NRTIs, is catalyzed by 
nucleoside diphosphate kinase. Purine metabolism is more complicated and complex 
than pyrimidine metabolism due to the fact that it must go through numerous extra steps 
involving adenyl ate kinase and other enzymes. The deoxyadenosine analog didanosine is 
an analog of the purine nucleoside inosine. For the case of the prodrug 6-Cl-ddP, it is 
transformed to the active drug, ddI, by the enzyme adenosine deaminase (Scheme 1). 
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Scheme 1. Transformation of 6-ClddP to 2'-3' .. ddI. 
Once the monophosphate ddI has been formed, the adenylate phosphorylation pathway 
may continue.6 There are many enzymes used to convert ddI to dideoxyadenosine 
monophosphate and all have been indentified. 7, 8 However all the necessary enzymes 
required in the phosphorylation of ddA-MP to ddA-TP have not yet been fully 
characterized but assumed to be adenylate kinase and nucleoside diphosphate kinase.6 
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Structure of Nucleoside Diphosphate Kinase 
The structure of nucleoside diphosphate kinase was realized through the crystal structure 
obtained by Janin et a1. 9 The cartoon of the structure follows in Figure 1. 
Figure 1. Crystal Structure of subunit of nucleoside diphosphate kinase. 
There are approximately 150 amino acid residues that make up the enzyme nucleoside 
diphosphate kinase. As with most proteins, NDP kinases are oligomeric, and in 
eukaryotes the enzymes are homohexamers. There is an a/~ domain, consisting of about 
90 residues that form the core of the subunit. The core represents a four-stranded anti-
parallel ~-sheet and two connecting a-helixes. The strand order comprising the ~-sheet is 
~2B3~I~4. ~I is connected to ~2 by the helix aI, while helix a3 connects strands ~3 to ~4. 
The ~-sheet, along with its two connecting a-helixes, characterize a structural 
configuration often times known as an a~ sandwich, or ~a~~a~ fold, or simply the 
ferrodoxin fold. The ferrodoxin fold is very common to many proteins. This structural 
element derived its name from its first observation in Pseudomonas aerogenes 
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ferrodoxin. As the a-helixes pack onto the ~-sheets, a well-maintained hydrophobic core 
is created. Strands ~1 and P3 are located in the middle of the sheet and are very 
hydrophibic, as evident by the amino acid residues. In order to extend the hydrophobic 
core to other subunits, strand ~2 has a leucine-rich sequence which fonns a "~-strand 
leucine zipper". This effectively promotes dimerization and burries the ~2 strand in the 
hydrophobic core even though it is an edge strand in the individual subunit. The 
majority of these proteins have one side of the beta-sheet covered by the two connecting 
a helixes, while the other side remains open. This is not the case for nucleoside 
diphosphate kinase. In NDP kinase both sides of the ~-sheet are covered. As mentioned 
previously, the bottom side is covered with the a-helixes 1 and 3, while the top is 
enshrouded by a pair of helixes, a-A-a-2, which is a hairpin centrally located betweens 
strands ~2' ~3 and helix a4. The active site ofNDP kinase is a histidine residue located at 
position 122 on the ~4 strand. It is positioned on the perilneter of the beta sheet and 
allows it to remain exposed for phosphorylation. Finalization of the subunit fold is 
acconlpolished by the addition of the Kpn loop and C-tenninal segment. The Kpn loop is 
22-residues in length, 96-117, and separates a3 and ~4' Consisting of the last 20 
residues, (134-152) in NDP Kinase B, the C-terminal segment is the final part of the 
subunit occurring after helix a4. The quaternary structure of the enzyme is very different 
between classes of organisms. In eukaryotes NDP kinase occurs as a hexamer, while in 
prokaryotes it is a tetramer (as in Myxoccus). The hexamer has a 70-A diameter and a 
50-A thickness. Its dihedral D3 symmetry can be viewed as three trimers related by 
symmetry. Two subunits can dimerize by beta-sheet extension to essentially fonn an 
eight-stranded antiparallel beta-sheet. The residues that make contact are located on 
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helix aI, strand ~2' and between residues 140 and 145 of the C-tenninal segment. At each 
dimer interface, there are approximately 10-12 hydrogen bonds. The Kpn loop and C-
tenninal residues 149-152 are the greatest donors to the trimer interface. The reason for 
this is because the tip of the loop is in close proximity to the threefold axis of the 
hexamer. In its entirety, six Kpn loops come together, three on the top face and three on 
the bottom, to confine a cavity composed of roughly 100 water molecules. A fissure 
fonns on the protein surface at the binding site about 20 A long, 6 A wide, and loA 
deep. At the bottom of the fissure, His118 can be resolved. The mechanisms of binding 
ofNDP kinase is all together different from that of a "classic" convention as seen in 
protein kinases such as adenylate kinase, ATPase, GTPase , and nucleoside 
monophosphate kinase. NDP kinase appears to have an anomalous binding mechanism. 
P4 is a short four-residue strand that contains the active-site residue, His 118, and is found 
immediately following the Kpn loop. A requisite for the loop to be connected to the p-
strand is a positive psi angle of residue 116. This residue is very often an isoleucine in 
most eukaryotes. The side chain of isoleucine should seem disinclined to fonn a positive 
psi angle due to its branching, yet this is what is seen experimentally. This pattern is 
essential to the function of the enzyme because had Ile116 a p-strand confonnation, the 
branched side chain would act as a hindrance and block the approach of the incoming 
nucleotide substrate from the imidazole group. A hydrogen bond from the NH of lIe 116 
to the side chain of Asp 14 conserves this unfavorable conformation. The N atom of the 
catalytic imidazole group of histidine can interact with the carboxylate of Glu129. This 
is not the only residue that Glu129 can interact with. Ser120, a residue in close proximity 
to the catalytic histidine on the p-strand, is involved in a His-Glu-Ser triad. The His 118 
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residue acts as a nucleophile, and the Glu129 residue acts as a base. The job ofGlu129 is 
to keep the imidazole group in the proper position as well as to keep the N protonated. 
The binding site on the enzyme will acknowledge ribose and 2'-deoxyribose, as well as 
other known nucleobases. The bound nucleotide is found between the aA-a2 hairpin and 
the Kpn loop. The base is located in proximity to the surface of the protein while the 
phosphate groups are contained within the enzyme and are angled towards the active-site 
residue. Comparing different protein structures with bound substrates shows that the 
base can move by 3--4 A depending on which base is used. This proves that the job of the 
binding site is to fit an array of groups. The sugar is located inside the bound enzyme 
complex away from the protein surface and has many polar interactions. The 2' -OH and 
3'-OH of ribose can hydrogen-bond to the amino group ofLys 12 and to the amide group 
of Asn 115. If the 2' -OH is missing, as in deoxyribose, a \vater tnolecule can take its 
place and have a minimal effect on the overall binding energy. The sugar assumes a C3' -
endo ring puckering, which directs the base into the anti-position. This is not the only 
confonnation that the binding pocket accepts. In order for dideoxyribose to bind, the 
sugar must assume a different ring pucker. The ~-phosphate folds back towards the sugar 
and fonns a hydrogen bond with the sugar 3'-OH. The oxygen is a leaving group when 
the active-site residue is phosphorylated by a nucleotide triphosphate, and by 
nlicroreversibility, an attacking group when the active site is dephosphorylated by a 
nucleotide diphosphate. This bond makes the connecting oxygen of the ~ and 'Y 
phosphate Inuch more reactive. It is shown to be very important due to the low activity 
of dideoxynucleotides. These analogs are phosphorylated 104-1 OS times less efficiently 
than other substrates.9 
9 
Cellular Factors Affecting Phosphorylation 
A large l'lumber of nucleoside diphosphate kinases are presented in the cell. to The 
turnover of the enzyme is very high, greater than 1000 fl, so therefore even a poor 
substrate will eventually be phosphorylated. I I, There are some cellular factors that can 
affect the rate of phosphorylation and have nothing to do with the substituent on or 
tnissing from the 3' -posi tion of the ribose ring. Metabolism may vary by cell type 
because different cell types are associated \vith different efficiencies of cellular kinases. 
Phosphorylation rates may be affected by the ddNTP:dNTP ratio present in the host cell. 
Common sense would predict a higher ratio of ddNTP to have a greater antiviral effect 
and result in greater inhibition of reverse transcriptase.7 Another factor affecting the 
phosphorylation rate of the nucleoside is the activation state of the cell. The 
phosphorylating activity varies in resting vs. stimulated cells for the different 
nucleosides. The final factor which could affect the rate of phosphorylation is the 
infection status of the cell. Whether or not the phosphorylation ability of an infected cell 
is altered from that of a non-infected cell is unknown. It is speculated that there would be 
higher dNTP levels in HIVMinfected individuals rather than uninfected ones.6 
Effective Treatment for Aids Dementia 
In order to treat AIDS delnentia there must be increased concentrations of 
dideoxynucleoside analogs delivered to the brain where the AIDS virus has penetrated 
the central nervous system (CNS). Didanosine (2' ,3' -dideoxyinosine, ddI) was the 
second NR TI approved for treatment by the FDA. As promising as the drug appeared, it 
had several delivery-related disadvantages.12 It had a highly variable bioavailability, btlt 
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more importantly, a low central nervous system uptake. The ability to construct antiviral 
agents that cross the central nervous system has become a daunting task due to the 
prevalence of the AIDS dementia complex, a progressive deterioration in mental capacity 
accompanying AIDS patients. I3 Since dideoxynucleosides are not very lipophilic, they 
penetrate the central nervous system very poorly. 14 There was a need for a prodrug that 
was inactive, yet capable of being altered back to the original active fonn by some 
enzynle-catalyzed reaction. The compound should address the lipophilicity problems and 
problenls associated with crossing the CNS which plagued the original NR TIs. The 
optimallipophilicity will correlate to the ideal intestinal absorption and membrane 
permeability. While achieving a high CNS penetration rate is advantageous, ones does 
not \vant to have too high of a rate to avoid passive diffusion across the blood-brain 
barrier. IS A solution to crossing the blood-brain barrier and increasing the concentration 
of the ddN reaching the CNS came about by going through a series of adenosine 
deaminase-actived 6-halo-dideoxypurine prodrugs. 16 Adenosine deaminase is present in a 
lO-fold higher concentration in the brain than in blood plasmal6. 6-Chloro-9-(2,3-
dideoxy-p-D-glycero-pentofuranosyl)purine (6-ClddP) provided a lO-fold increase in 
concentration of delivery of ddI to the brain parenchyma compared to ddI controls l6 . 
This effective increase in concentration can be attributed to the increased lipophlicity of 
6-ClddP and to its conversion to ddI inside the brain. As stated earlier, this conversion is 
realized \vith the use of the enzyme, adenosine deaminase (Scheme 1 ).12 The mechanism 
of conversion is nucleophilic aromatic substitution where a water molecule in the active 
site of the enzyme is the nucleophile. 6-ClddP crosses the blood-brain barrier with nluch 
more efficiency than ddI because it is roughly 30 times more lipophilic. 
11 
Modeling Approach 
Since the 2' and 3' -OHs are missing from the nucleotides, there is going to be a change in 
conformation upon binding. There have been several crystal structures obtained for the 
enzyme, including itself in the free state, the phosphorylated intermediate, and the 
enzyme complexed with endogenous nucleosides such as ADP and GDP .17 
Unfortunately there have been no crystal structures obtained for the enzyme complexed 
with dideoxypurine nucleosides. The 'Y-phosphate of a nucleoside triphosphate is 
transferred by NDP kinase through a phosphohisitdine intermediate onto a nucleoside 
diphosphate.I 8 Human nucleoside diphosphate kinase complexed with ADP was 
modeled using SYBYL 7.2 on a Silicon Graphics workstation using the Tripos forcefield. 
Utilizing the crystallographic data from protein data bank number 2HVD, and 
incorporating the methods of Hutter et al,3 a model of the active site was set up for the 
computational investigation of the enzyme NDP kinase. The residues considered in 
vicinity of the active His 118 and ADP included: Glu 129, Lys 12, Asn 115, Val 112 and 
Phe 60 (Figure 2). 
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Figure 2. Binding pocket of NDP kinase for nucleoside with labeled residues. 
Hydrogen atoms \vere added prior to the computation to ensure that all side chains 
remained protonated. See Table 1 for a listing of key interactions of ddI DP complexed 
with the enzyme. 
Key interactions of ddI DP complexed 
withNDPK 
~-phosphate oxygen hydrogen bond with 
His 118 2.67 A 
Key interactions of ADP complexed with 
NDPK 
2' and 3'-OH H .. bond to Lys 12 and Asn 
115 
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Hydrogen bond between Glu 129 and His-Glu-Ser triad (as described earlier) 
Ser 120 
Lys 12 and Asp 115 hydrogen bond This interaction is not seen 
Intramolecular bonding between phosphate No intramolecular bonding between 
atoms phosphate 
1t stacking between Phe 60 and nitrogenous Val 112 and Phe 60 encompase the base as 
base 3.98 A it sits in the binding pocket 
Table 1. Key interactions of ddI DP complexed with NDP kinase 
Discussion of Modeling 
SYBYL predicted a hydrogen bond from the beta phosphate oxygen to the catalytic His 
118, which was not seen on the original ADP enzyme complex (Figure 3). 
Figure 3. SYBYL predicted H-bonds with bound ddI DP. 
14 
Intramolecular bonding of the phosphates of ddI was also shown as a possibility after 
acquisition using Tripos forcefield. Other important interactions analyzed were the 
hydrophobic ones that involved 1C stacking between the nitrogenous bases, Phe60, and 
Va1112. In the ADP enzyme complex Val112 and Phe60 incompases the base, and the 
distance behveen the center of the base and the center ofPhe 60 is less than 3.5 A. In 
contrast, Val112 has no interaction between ddI, and Phe60 is shifted to produce a 3.98 A 
1t stacking interaction between the two ring systenls. 
Synthesis of 6 .. chloro .. 9 .. (2,3 .. dideoxy .. p-D .. glycero .. pentofuranosyl)purine 
The D~glycero.pentofuranose ring system is synthesized from commercially 
available L-glutanlic acid. The reaction can be considered to involve a diazotization by 
interaction ofN203 (HN02) with the amino group on L-glutamic acid. This leads to the 
fonnation of a diazonium ion, a good leaving group. (Scheme 2). 
o 
II 
(6H @~ _He 
R-NH2 ------•• R-N-N=O ------~. R-N-N=O 





---.... R-N=N (f) 
... 
Scheme 2. Carbocation intermediate of N .. nitrosation. 
A sensible mechanism that would produce (S)-(+)-carboxy .. ,,(-butyrolactone very rapidly 
would be one where the ,,(-carboxyl group acts as a lluc1eophile. (Scheme 3). 
15 
Configuration will be preserved due to the neighboring-group participation effect of the 
adjacent a-carboxyl group. Once the cyclic carbonium iOll is fonned, simple 





Scheme 3. Synthesis of (S)-(+) .. Carboxy-y .. butyrolactone. 
BH3, a strong Lewis acid, is used as the reducing reagent for the carboxylic acid 
on the above lactone. It is an electron acceptor and can interact with lone pairs of 
electrons or nucleophiles. Diborane does not exist as free BI-I3 but rather as the diborane 
dimer B2H6 or complexed with a Lewis base. Diborane shows nUlnerous differences in 
its reducing power than those portrayed by the alkali metal borohydrides. During the 
early 1960s carboxylic acids were normally considered to be relatively resistant to 
reducing agents, but this all changed with the introduction and commercial availability of 
diboranc, which converts carboxylic acids to the corresponding alcohols very rapidly.2o 
It is a very versatile reducing agent because it produces high yields with ease of isolation 
of products over a variety of functional groups. Methylsulfide'borane (DMSB) is 
advantageous in this case over the use ofborane'THF (BTHF) complex for two reasons. 
Firstly DMSB is not as reactive as BTHF due to the stronger coordination ofborane to 
Me2S, This assures that DMSB will not over-reduce the ring. Secondly DMSB is very 
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stable and can be produced and used in high concentrations. The first step in the 
reduction is the formation of triacylborane. Since the electron deficiency of the boron 
atom exerts a powerful demand on the lone pairs of the acyl oxygen, the resonance that 
occurs is between the boron atom and the oxygen atom rather than the carbonyl group as 
proposed by Brown et al. 20 (Schen1e 4). 
Scheme 4. Resonance between boron and oxygen atoms 
that the carbonyl groups of the triacylboranes now resemble those of aldehydes or 
ketones more closely than those of esters (Scheme 5).20 
Scheme 5. Synthesis of (S)-(+)-Hydroxymethyl-y-butyrolactone. 
Protection of the hydroxyl groups via sHyl ethers is very important to synthetic 
organic chemistry. The general order of stability of the protection groups towards acidic 
media are TMS (1) < TES (64) < TBS (20,000) < TIPS (700,000) < TBDPS (5,000,000) 
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and the stability towards basic media is TMS (1) < TES (10-100) < TBS""" TBDPS 
(20,000). The tert-butyldiphenylsilyl (TBDPS) moiety was chosen as the protecting 
group because the reaction is run in base, and it allows one to monitor reaction progress 
since, \vhen absorbed onto a TLC sheet, the TBDPS moiety absorbs UV light. This 
reaction is catalyzed by 4-dimethylaminopyridine (4-DMAP) because it is a powerful 
electron-donating group and aids in the formation of a charged intermediate.21 . Once the 
charged intennediate is formed, the reaction proceeds sitnilar to that of a Williamson 
ether synthesis following an SN2 fashion (Scheme 6). 
.. 
+ J-\\ / : N \ N 
- \ 
Scheme 6. Synthesis of S-(+)-tert-butyldiphenylsilyloxymethyl-y-butyrolactone 
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During the next stage in the synthesis, the lactone, a cyclic ester, is reduced to a 
lactol. Over-reduction is prevented by the hemiacetal functionality that essentially 
"masks" the aldehyde. Diisobutylaluminumhydride (DffiAL-H) is the reducing reagent 
and used at -78 °C to prevent over-reduction. A proposed mechanism follows in Scheme 
7. 
n (-
+y """v-0yO---AI 2) ° U~H )-
OH-
Scheme 7. Synthesis of 5-0-tert-butyldiphenylsilyl-2,3-dideoxy-n-glycero-
pentofuranose. 
During the coupling step of the synthesis, the anomeric hydroxyl group is 
converted to a trifluoroacetyl ester. This group is a very good leaving one-much better 
than the hydroxyl group. The trifluoroacetyl group is very reactive, and thus the reaction 
must take place at -40 °C and under strictly anhydrous conditions. The trifluoroacetyl 
ester and 6-CI purine group are safe in basic media, so pyridine is a logical choice as the 
catalyst. An oxonium ion is formed, and the coupling reaction can proceed by a 







lL .. J- ~ N N 
• TBDPSIO~ 
Scheme 8. Synthesis of 6-chloro-9-[5-0-(tert-butyldiphenylsilyl)-2,3-dideoxy-p-D-
glycero-pentofuranosyl]purine. 
The final step in the synthesis is the deprotection of the tert-butyldiphenylsilyl 
group. This is achieved by tetrabutylammonium fluoride (TBAF) (Scheme 9). 
20 
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All solvents and reagents used for this synthetic approach were reagent grade. 
The solvents were anhydrous and dried as follows: dichloromethane (CH2Ch), pyridine, 
toluene, and acetonitrile (CH3CN) were distilled from calcium hydride; tetrahydrofuran 
(THF) was dtied over sodium-bel1zophenone ketyl and distilled. All solvents were 
prepared fresh and stored in clean, dry glassware in a desiccator prior to use. After 
reactions were complete, excess solvents were evaporated using a Bilchi rotary 
evaporator and a wann water bath with temperatures no higher than 40 °C. There were 
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some evaporations carried out at very low pressures, and these nlade use of a 
high-vacuum rotary evaporator. Reaction progress was monitored by TLC on aluminum-
backed plates. Products were separated using column chromatography, which was 
achieved using coarse 70-230 Mesh ASTM silica gel. The TLC plate was visualized 
under UV light of 254-nm and also by dipping in anisaldehyde-sulfuric acid in ethanol, 
followed by a short blast of heat from a heat gun. 
B. Preparation of Compounds 
Synthesis of (S)-(+)-Carboxy...y-butyrolactone (2) 
A suspension ofL-glutamic acid (1, 50 g, 0.34 mol) in concentrated HCL (72 mL) and 
H20 (130 mL) was cooled to -5 °C in a round-bottolll flask. To this suspension was 
added dropwise over a period of 3 h a solution of sodium nitrite (NaN02, 35 g, 0.50 mol) 
in H20 (75 mL). It is very important that the temperature be kept at -5 °C during the 
entire addition. The reaction was slowly warmed to room temperature and allowed to stir 
for 48 h. The water was evaporated with the use of a high-vacuum rotary evaporation 
apparatus and a wann water bath of 50 °C. The product was freeze-dried using a 
bench-top lyophilizer which converted the yellowish syrup into a white-yellow solid. 
The solid was extracted \vith EtOAc (200 mL), suction filtered, and dried over anhyd 
MgS04. After the MgS04 was filtered from the product, the EtOAc was rotary 
evaporated and the product dried under high-vacuum, resulting in a yellowish syrup that 
was further dried in a drying pistol (CH2Ch reflux) for 48 h to produce the product 2 
(30.6 g, 235 mmol, 61.2%) as a pale-yellow solid. 
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Physicochemical data: IH NMR (CDCh, 300 MHz): 02.3-2.73 (m, 4H, H-2 and 
H-3), 4.97 (m, 1H, H-4), 9.8 (bs, 1H, H-5), [Lit.22 CD30D, 100 MHz): 1.8-2.3 (m, 4H, 
H-2 and H-3), 4.2 (m, 1H, H-4)] 
Synthesis of (S)-(+)-Hydroxymethyl-y-butyrolactone (3) 
To a solution of (S)-(+)-carboxy-y-butyrolactone (2, 5.0 g, 38 mmol) in anhyd THF (20 
mL) at -78°C (dry-ice-acetone bath) was added a solution of2 M borane·methyl sulfide 
complex in THF (22 mL, 44.2 mmol) over the period of 1 h under a nitrogen atmosphere. 
The temperature of the addition was kept at -78°C. The mixture was stirred for 5 hat -78 
°C with constant monitoring of the temperature and cooling when required. The reaction 
mixture was quenched by cautiously adding dry MeOH (20 mL) at -78°C, and the 
product was co evaporated with methanol three times. After high-vacuum rotary 
evaporation, the product was placed on the high-vacuum pump overnight and dried to 
produce 3 (3.95 g, 34 mmol, 79%) as a pale-yellow oil. 
Physicochemical data: bp 125-135 °Clhigh-vacuum, (Lit.22 131-147 °C/7mm); 
IH NMR data (CDCh, 300 MHz): 02.05-2.75 (m, 4H, H-2 and H-3), 3.6-3.95 (m, 3H, 
H-5 and H-6), 4.58--4.68 (m, 1H, H-4), [Lit.22 (100 MHz) 2.0-2.8 (m, 4H, H-2 and H-3) 
3.6--4.0 (m, 3H, H-5 and H-6), 4.65 (m, IH, H-4)]. 
Synthesis of (S)-(+)-tert-Butyldiphenylsilyloxymethyl-'Y-butyrolactone (4) 
A solution of (S)-(+)-hydroxymethyl-y-butyrolactone (3, 3.9 g, 34 mmol), 4-
dimethylaminopyridine 4-DMAP (0.1 g, 0.8 mmol), and pyridine (2 mL, 25 mmol) was 
dissolved in dry CH2Ch (40 mL) at room temperature under anhydrous conditions and 
under a nitrogen atmosphere. To this mixture was added tert-butyldiphenylsilyl chloride 
TBDPS-CI (10.6 mL, 40.8 mmol) dropwise over the course of 1 h. The reaction mixture 
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was allowed to stir for 24 h at room temperature and was further refluxed for 3 h; 
reaction progress \vas monitored by TLC. The reaction mixture was allowed to cool to 
room temperature where it was washed with H20 (2 x 25 mL). After the organic layer 
was separated it was dried over anhyd MgS04 to remove any residual water, producing a 
yellow-brown syrup. Column chromatography, with an eluent consisting of hexane-
CH2Ch. followed by an increasing ratio of dichloromethane, was used to purify the syrup. 
The desired fractions were collected, and the product was recrystallized from hexane to 
yield 4 (8.2 g, 23.12 mnlol, 68%). 
Physicochemical data: Rf 0.35 (4:1 CH2Ch-hexane); IH NMR data (CDCh, 300 
MHz): 80.98-1.05 (s, 9H, tert-butyl), 2.1-2.75 (m, 4H, H-2 and H-3), 3.63-3.89 (2dd, 
2H, H-5), 4.55-4.65 (m, 1H, H-4), 7.35~7.7 (m, 10H, phenyl), [Lit.23 (250 MHz) 8 LO-
Ll (s, 9H, tert-butyl), 2.1-2.8 (m, 4H, H-2 and H-3), 3.6-3.9 (2dd, 2H, H-5), 4.5-4.7 (m, 
1H, H-4), 7.3-7.8 (m, lOH, phenyl). 
Synthesis of 5-0-tert-butyldiphenylsilyl-2,3-dideoxY-D-glycero-pentofuranose 
(5) 
(S)-(+)-tert-butyldiphenylsilyloxymethyl-y-butyrolactone (4, 5.0 g, 14 mmol) was 
dissolved in dry PhCH3 (50 mL) in a dry round-bottom flask with a dry stir bar under a 
nitrogen atmosphere. The flask and its contents were cooled to -78°C (dry-ice-acetone 
bath) and was added cautiously diisobutylaluminumhydride DIBAL-H (15.2 mL, 1.2 M 
PhCH3, 18.4 mmol) over the course of 30 min. The reaction was allowed to stir for 4 h 
while the temperature was maintained at -78°C, cooling when necessary. To quench the 
reaction, several crystals ofNa2S04'10 H20 were added at -78°C. The cold bath was 
removed, and the reaction mixture was allowed to warm to room temperature. 
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Dichloromethane (20 mL) was added, followed by anhyd MgS04 (1 g), and the reaction 
mixture was allowed to stir for 30 mins. The mixture was vacuum filtered and the 
precipitate was washed with warm 1: 1 CHCh-EtOAc in order to dissolve the aluminum 
complex formed and until the filtrate \vas no longer UV active. The solvent was 
evaporated, and the product was purified by column chromatography eluting with 
hexane, 3:1 hexane-CH2Ch, and 2:1:1 hexane-CH2Cb-EtOAc. After collection of the 
desired fractions and after recrystallization from hexane, product 5 (4.12 g, 11.57 mmol, 
82.1 %) was realized as white crystals. 
Physicochemical data: RfO.6 (2:1:1 hexane-CH2Cb-EtOAc); IH NMR data 
(CDCb, 300 MHz): 8 .95-1.05 and 1.5 (s, 9H, tert-butyl), 1.75-2.2 (m, 4H, H-2 and 1-I-
3), 1.7-2.1 and 2.5 (s, I-H), 3.2-3.85 (2dd, 2H, H-5, 4.15-4.4 (m, IH, H-4), 5.35-5.55 
(M-1H, H-1), 7.35-7.75 (m, 10H, phenyl), [Lit.23 (250 MHz) 1.0 and 1.5 (s, 9H, tert-
butyl), 1.7-2.2 (m, 4H, H-2 and H-3), 2.0 and 2.4-2.5 (s, 1H, -OH), 3,3-3.9 (2dd, 2H, H-
5),4.1-4.4 (m, 1H, H-4), 5.4-5.6 (m, H, H-1), 7.3, 7.8 (m, lOR, phenyl). 
Synthesis of 6 .. Chloro-9-[5-0-(tert-butyldiphenylsilyl)-2,3-dideoxy-p .. D-glycerQ-
pentofuranosyl]purine (6) 
5-0-tert-butyldiphenylsilyl-2,3-dideoxY-D-glycero-pento furanose (5, 0.115 g, 
0.322 mmol) was massed into a dry round-bottom flask (flask 1) with a stir bar and 
placed on the pump overnight to insure complete dryness. In a separate flask (flask 2) 
anhyd K2C03 (0.014 g, 0.10 mmol), benzyltriethylammonium chloride (BTEAC) (0.06 g, 
0.26 mmol) and 6-chloropurine (0.06 g, 0.39 mmol) were also placed on the pump 
overnight. Freshly distilled THF (10 mL) was added to flask 1 and cooled to -78°C, 
followed by addition oftrifluoroacetic anhydride (TF AA), (0.06 mL, 0.42 mmol) and 
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pyridine (0.03 mL, 0.4 mmol). The reaction mixture was warmed to .. 40°C to .. 20 °C and 
allowed to stir for 2 h, cooling when necessary. Anhyd CH3CN (10 mL) was added to 
flask 2, and the mixture was cooled to 0 °C using an ice bath. The cold bath was removed 
fronl flask 1, and with the aid of a cannula, the reaction mixture was transferred from 
flask 1 to flask 2. The resulting mixture was slowly wanned to room temperature where 
it was stirred for an additional 10 h. After evaporation of the solvent~ a brown 
sludge/syrup "vas left in the flask. After addition ofCH2Ch (25 roL) and stirring for 10 
min, vacuum filtration proceeded by high vacuum rotary evaporation, produced a brown 
residue. Silica gel chromatography was used to purify the residue; a concentration 
graded eluent was used. Initially 95% petroleum ether to 5% EtOAc was used as the 
eluent. The concentration of EtOAc "vas increased by 5% every 100 mL of eluent until 
the concentration reached 65% pet. ether to 35% EtOAc. Recrystallization from hexane 
afforded the product 6 (0.136 g, 0.2763 Inmol) from which the ~-anomer was separated to 
yield 0.09 g, 0.182 mmol, 56.7%. 
Physicochemical data: Rf 0.52 (1: 1 hexane-EtOAc); IH NMR data (CDCh, 300 
MHz): 8 1.05-1.1 (5, 9H, tert-butyl), 2.05-2.3 (m, 2H, H .. 3'), 2.53-2.63 (m, 2H, H .. 2'), 
3.7-4.0 (2dd, 2H, H'5), 4.25-4.35 (m, 1H, H .. 8), 6.35-6.4 (t, IH, H.,l '), 7.32-7.68 (In, 
lOR, phenyl), 8.48 (s, IH, H-8), 8.7 (5, 1H, R-2), [Lit.23,24 1.00-1.1 (8, 9H, tert-butyl), 
2.05-2.25 (m, 2H, H-3'), 2.5-2.65 (m, 2H, H .. 2'), 3.7-4.0 (2dd, 2H, H-5'), 4.25-4.4 (m, 
1H, H-4'), 6.35-6.42 (t, IH, H-l '), 7.3-7.70 (mt 10H, phenyl), 8.45 (8, 1H, H-8), 8.7 (5, 
IH! H-2)] 
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Synthesis of 6 .. Chloro-9-(2,3 .. dideoxy .. p-D-glycero .. pentofuranosyl)purine (7) 
6-Chloro-9-[5-0-(tert-butyldiphenylsi1yl)-2,3-dideoxy-~ .. D-glycero-
pentofuranosyl]purine (6, 0.2 g, 0.4 mmol) was dissolved in anhyd THF (10 mL), and 
tetrabutylammonium fluoride TBAF (0,9 mL, 1M THF, 0.89mmol) was added, Next was 
added triethylamine (TEA, 0.06 g, 0.55 mmol) and HOAc (0.03 g, 0.5mmol) in THF (5 
mL) dropwise. This mixture was stirred for 1 h, the solvent was evaporated, and the 
product was purified on silica gel. The eluent consisted of58:1 CHCh-MeOH. 
Collection and evaporation of the desired fractions yielded (8, 0.09 g , 88%) of a white 
crystalline product after recrystallization from hexane. 
Physicochemical data: Rr 0.62 (9: 1 CHzCh~MeOH); IH NMR data (CDCI3, 300 
MHz) 2.15-2.75 (m, 4H, H-2' and H-3'), 3.68-4.08 (2dd, 2H, H-5'), 4.3-4.45 (m, 1H, H-
4'), 6.28 (t, IH), 8.46 (s, 1 H), 8.75 (s, IH), [Lit.24 1.95-2.8 (m, 4H), 3.88 (m, 2H), 4.38 
(m, 1H), 6.31 (t, IH), 8.5 (8, IH), 8.74 (s, IH)] 
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